Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

Gilead, its investors, and AIDS activists have high hopes for Yeztugo. Approved in June for people at high risk of HIV, the drug was shown to be nearly 100% effective at preventing infection in large ...

Patients are being urged to order repeat prescriptions in advance of the upcoming bank holiday. The advice comes from the North East and North Cumbria Integrated Care Board (ICB), which is reminding ...

"In a technology-driven climate, effort should be made to recognize that receiving buprenorphine prescriptions from a ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

THE NHS is set to dish out Mounjaro prescriptions to more patients, as private clinics prepare to double their prices from ...

The U.S. compounding pharmacies market size reached USD 6.10 billion in 2024 and is expected to grow from USD 6.45 billion in 2025 to USD 10.93 billi ...